March 30, 2026 —
Lexeo Therapeutics has announced significant progress across its AAV-based gene therapy pipeline for cardiovascular diseases, highlighting advancements in its lead programs LX2006 and LX2020, as well as new regulatory and strategic milestones supporting the development of cardiac genetic medicines.
The company reported that the SUNRISE-FA 2 pivotal clinical trial protocol and statistical analysis plan (SAP) for LX2006, an investigational AAV gene therapy for Friedreich ataxia (FA) cardiomyopathy, was submitted to the U.S. Food and Drug Administration (FDA) in the first quarter of 2026 following a Type B regulatory meeting. Lexeo expects to receive final FDA feedback in the second quarter of 2026 and plans to initiate the open-label pivotal study in the first half of 2026.
LX2006 is designed to address the cardiac complications associated with Friedreich ataxia by delivering a functional gene intended to restore normal cellular function in heart tissue. Interim results from ongoing Phase I/II clinical studies have shown encouraging outcomes, including improvements in cardiac structure and function, reductions in left ventricular mass index (LVMI), and positive trends in neurological function measured by the modified Friedreich Ataxia Rating Scale (mFARS). The therapy has also demonstrated a favorable safety profile, with no Grade 3 or higher serious adverse events reported to date.
In November 2025, the FDA approved the analytical comparability between HEK293 and Sf9 manufacturing processes for LX2006, allowing the use of the optimized Sf9-based commercial manufacturing platform in the planned pivotal study. More recently, Lexeo held its first Chemistry, Manufacturing and Controls (CMC) Development and Readiness Program (CDRP) meeting with the FDA in early 2026. During this meeting, regulators supported a flexible validation strategy, including the possibility of reduced process performance qualification (PPQ) manufacturing runs, helping streamline the path toward Biologics License Application (BLA) submission.
Additional clinical progress was highlighted at the American College of Cardiology (ACC) Annual Meeting, where Lexeo presented late-breaking data from both the LX2006 and LX2020 programs. Updated results from the LX2006 trial demonstrated sustained or deepening improvements in both cardiac and neurological measures in treated patients.
Lexeo also reported progress with LX2020, an investigational AAV gene therapy targeting PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Interim data from the HEROIC PKP2 Phase I/II trial showed dose-dependent increases in PKP2 protein expression, vector copy number, and transgene mRNA in cardiac biopsy samples. In higher-dose cohorts, participants experienced reductions in arrhythmia burden and improvements in symptoms, while maintaining a favorable safety profile.
Beyond clinical development, Lexeo announced a research collaboration with Johnson & Johnson to explore targeted cardiac delivery approaches for AAV gene therapies. The collaboration will combine Lexeo’s expertise in cardiac genetic medicine with Johnson & Johnson’s cardiovascular technologies, including Impella™ heart pumps, to evaluate novel localized delivery routes for viral gene therapy directly to heart tissue.
The company also strengthened its leadership team with the appointment of Narinder Bhalla, MD, as Chief Medical Officer, bringing extensive experience in clinical development and global product launches from roles at Bristol Myers Squibb and AstraZeneca.
Financially, Lexeo reported $246.6 million in cash, cash equivalents, and investments, which the company expects will provide operational runway into 2028. This funding position has been strengthened by a $154 million equity financing completed in October 2025, aimed at advancing the company’s cardiovascular gene therapy programs and preparing LX2006 for potential registrational development.
Together, these updates underscore Lexeo’s strategy to advance precision AAV gene therapies for cardiovascular diseases, an emerging area where targeted genetic interventions could address the underlying molecular causes of serious heart conditions.
